Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 13/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13134373 | 0.88 | STING1 (0.56) | STING1GPR84 | |
| SCHEMBL747027 | 0.85 | STING1 (0.55) | STING1GPR84 | |
| SCHEMBL28736881 | 0.81 | STING1 (0.74) | STING1GPR84 | |
| SCHEMBL25248545 | 0.80 | NPSR1 (0.46) | EGFR | |
| SCHEMBL30934607 | 0.80 | NPSR1 (0.46) | EGFR | |
| SCHEMBL4490274 | 0.80 | STING1 (0.59) | STING1GPR84 | |
| SCHEMBL384965 | 0.80 | STING1 (0.63) | STING1GPR84 | |
| SCHEMBL16339546 | 0.79 | MAPK1 (0.56) | PTPN1PTPN11TGM2 | |
| SCHEMBL30684894 | 0.79 | MAPK1 (0.56) | PTPN1PTPN11TGM2 | |
| SCHEMBL1596152 | 0.78 | STING1 (0.61) | STING1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569281-A1 | NOVEL METHODS FOR THE PREPARATION OF P2X7R ANTAGONISTS | Affectis Pharmaceuticals AG (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-20130060047-A1 | NOVEL METHODS FOR THE PREPARATION OF P2X7R ANTAGONISTS | AFFECTIS PHARMACEUTICALS AG (DE) | 2013-03-07 | — | — | US | disclosed |
| US-20130060047-A1 | NOVEL METHODS FOR THE PREPARATION OF P2X7R ANTAGONISTS | AFFECTIS PHARMACEUTICALS AG (DE) | 2013-03-07 | — | — | US | disclosed |
| CN-102858741-A | Novel methods for the preparation of P2X7R antagonists | AFFECTIS PHARMACEUTICALS AG | 2013-01-02 | — | — | CN | disclosed |
| WO-2011141194-A1 | NOVEL METHODS FOR THE PREPARATION OF P2X7R ANTAGONISTS | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-11-17 | — | — | WO | disclosed |
| EP-2386541-A1 | Novel methods for the preparation of P2X7R antagonists | Affectis Pharmaceuticals AG (DE) | 2011-11-16 | — | — | EP | disclosed |
| EP-2386541-A1 | Novel methods for the preparation of P2X7R antagonists | Affectis Pharmaceuticals AG (DE) | 2011-11-16 | — | — | EP | disclosed |
| US-20100247938-A1 | MATERIAL FOR THREE-DIMENSIONAL MODELING, PROCESS FOR PRODUCING THREE-DIMENSIONAL MODEL, AND THREE-DIMENSIONAL MODEL | FUJIFILM CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100247938-A1 | MATERIAL FOR THREE-DIMENSIONAL MODELING, PROCESS FOR PRODUCING THREE-DIMENSIONAL MODEL, AND THREE-DIMENSIONAL MODEL | FUJIFILM CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060047-A1 | NOVEL METHODS FOR THE PREPARATION OF P2X7R ANTAGONISTS | P2RX7, P2RX3, P2RX2 | STING1 1473/4885PTPN1 1441/4885PTPN11 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.